Cyclosporine: Mechanism of Action and Source
Cyclosporine is a cyclic polypeptide immunosuppressant isolated from the soil fungus Tolypocladium inflatum (also known as Beauveria nivea), consisting of 11 amino acids with a molecular weight of 1203 Da, first discovered in 1970 1, 2.
Source and Chemical Structure
Cyclosporine is produced as a metabolite by the fungus species Tolypocladium inflatum 1. It is a neutral, hydrophobic, cyclic polypeptide containing 11 amino acids 1. The drug is not synthetically manufactured but rather derived from this naturally occurring fungal source, which was originally isolated from soil samples 1.
Mechanism of Action
Primary Mechanism: Calcineurin Inhibition
Cyclosporine functions as a potent, noncytotoxic immunosuppressive agent by specifically suppressing T-helper cell responses through inhibition of lymphocyte activation 1. The mechanism operates through the following pathway:
- Cyclosporine binds to cytoplasmic cyclophilin, a family of cis-trans isomerases (peptidyl-prolyl isomerases) 1
- This cyclosporine-cyclophilin complex inhibits calcineurin phosphatase 1
- Calcineurin normally dephosphorylates the nuclear factor of activated T cells (NFAT) 1
- By blocking calcineurin, cyclosporine prevents NFAT from entering the nucleus and promoting transcription of key lymphokines 1
Cytokine Suppression
The calcineurin inhibition results in reduced production of multiple critical cytokines, including 1:
- Interleukin-2 (IL-2) - the primary target
- Interferon-gamma
- Granulocyte-macrophage colony-stimulating factor
- IL-3, IL-4
- Tumor necrosis factor-alpha (TNF-α)
This represents specific and reversible inhibition of immunocompetent lymphocytes in the G0 and G1 phases of the cell cycle, with T-lymphocytes preferentially inhibited 2.
Additional Mechanisms
Beyond the primary calcineurin/NFAT pathway, cyclosporine exhibits other immunomodulatory properties 1:
- Inhibits antigen-presenting cell function
- Blocks release of mast cell mediators including histamine and prostaglandins
- Inhibits keratinocyte proliferation and cytokine secretion
- Blocks JNK and p38 signaling pathways triggered by antigen recognition 3
Important Clinical Distinction
Cyclosporine does not cause bone marrow suppression, distinguishing it from cytotoxic immunosuppressants 2. It acts through immunomodulation rather than cytotoxic mechanisms, making it a "noncytotoxic immunosuppressive agent" 1.
Clinical Relevance
The drug has a narrow therapeutic index, requiring careful monitoring to balance efficacy against toxicity, particularly nephrotoxicity and hypertension 1. The immunosuppressive activity is primarily due to the parent drug, with elimination occurring primarily through biliary excretion (only 6% excreted in urine) and a terminal half-life of approximately 8.4 hours (range 5-18 hours) 2.